Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Immuneering Corporation

IMRX ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$3.81

▲ +1.87%

Market Cap $246.50M · Vol 118.54K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$246.50M

Micro Cap

Div Yield

N/A

EPS Growth

+11.91%

YoY

RSI (14)

41.88

Momentum

Beta

0.47

vs Market

52W High

$8.48

55.90% below

52W Low

$3.40

10.16% above

Volume

118.54K

Avg 175.59K

P/B

1.95

Price-to-book

ROE

N/A

Return on equity

Free Float

86.08%

Public shares

Shariah Compliance8 STANDARDS

✗ Immuneering Corporation (IMRX) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IMRX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+4.67%

-17.35%

-14.77%

-35.31%

YTD

-42.10%

-28.79%

-32.92%

-85.26%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-56,024,900.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-39.36% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.95
P/FCF	N/A
EPS Growth	+11.91%
Outstanding Shares	64.70M

Technical Indicators

50-Day SMA	$4.44
200-Day SMA	$4.85
RSI (14)	41.88
Beta	0.47
52-Week High	$8.48
52-Week Low	$3.40

Volume Today	118.54K
Avg Daily Volume (30D)	175.59K
Relative Volume	0.68x
Volatility (10D)	64.06
Volatility (30D)	50.33
Free Float	86.08%

Analyst Consensus

BUY

Current Price $3.81

Mean Target $17.17

52W Low$3.40 52W High$8.48

Current

Target

$3.40 $8.48

Current Analyst target

+350.57% upside potential · 7 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG009QXJQV7

ISINUS45254E1073

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -6.02% ARGX.BR argenx SE -0.41% ARGX argenx SE -1.61% GMAB.CO Genmab A/S +1.30% GMAB Genmab A/S +1.09%

Company Profile

Immuneering Corporation is a late-stage clinical oncology company, with an initial focus on patients with RAS, RAF and other mitogen-activated protein kinase (MAPK)-driven cancers. The Company's lead product candidate, atebimetinib (IMM-1-104), is an investigational, oral, once-daily Deep Cyclic Inhibitor of MEK. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company's development pipeline also includes its additional clinical-stage product candidate envometinib (IMM-6-415) and other pre-clinical research programs, including research focused on validated core cancer-signaling pathways outside of the MAPK pathway. The Company's Deep Cyclic Inhibition (DCI) platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling. Its Deep Cyclic Inhibitors inhibit clinically-validated core signaling pathways, such as the MAPK pathway.